{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:55:09Z","timestamp":1787223309719,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.lungcan.2023.107280","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T04:49:48Z","timestamp":1686890988000},"page":"107280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Reduced risk of secondary primary extra pulmonary cancer in advanced\/metastatic lung cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-549X","authenticated-orcid":false,"given":"P.E.","family":"Heudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Montfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stancu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Quantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hiret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2023.107280_b0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107280_b0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107280_b0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11523-016-0459-0","article-title":"Risk of Second Primary Malignancies in Lung Cancer Survivors - The Influence of Different Treatments","volume":"12","author":"Su","year":"2017","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107280_b0020","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-94","article-title":"The effect of patient characteristics on second primary cancer risk in France","volume":"14","author":"J\u00e9gu","year":"2014","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2023.107280_b0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.21037\/jtd.2018.11.96","article-title":"Effect of second primary cancer on the prognosis of patients with non-small cell lung cancer","volume":"11","author":"Wu","year":"2019","journal-title":"J. Thorac. Dis."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107280_b0030","doi-asserted-by":"crossref","first-page":"e0209002","DOI":"10.1371\/journal.pone.0209002","article-title":"Incidence trends and risk prediction nomogram of metachronous second primary lung cancer in lung cancer survivors","volume":"13","author":"Hu","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.lungcan.2023.107280_b0035","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1080\/03007995.2017.1333953","article-title":"Subsequent thoracic cancers among patients diagnosed with lung cancer: a SEER database analysis","volume":"33","author":"Abdel-Rahman","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.lungcan.2023.107280_b0040","doi-asserted-by":"crossref","unstructured":"Druesne-Pecollo N, Keita Y, Touvier M. et al. Alcohol drinking and second primary cancer risk in patients with upper aerodigestive tract cancers: a systematic review and meta-analysis of observational studies. Cancer Epidemiol. Biomarkers Prev. 2014;23(2):324\u2013331.","DOI":"10.1158\/1055-9965.EPI-13-0779"},{"issue":"10","key":"10.1016\/j.lungcan.2023.107280_b0045","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1093\/annonc\/mdt279","article-title":"Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study","volume":"24","author":"Tabuchi","year":"2013","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107280_b0050","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6605616","article-title":"Risks of second primary cancer among patients with major histological types of lung cancers in both men and women","volume":"102","author":"Chuang","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107280_b0055","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3892\/mco.2015.594","article-title":"Metachronous second primary lung cancer surgically treated five years or more after the initial surgery","volume":"3","author":"Koezuka","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107280_b0060","doi-asserted-by":"crossref","unstructured":"Choi E, Luo SJ, Aredo JV, et al.The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer. J. Natl. Cancer Inst. 2022 Apr 11;114(4):618-625. 10.1093\/jnci\/djab224. PMID: 34893871.","DOI":"10.1093\/jnci\/djab224"},{"issue":"21","key":"10.1016\/j.lungcan.2023.107280_b0065","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2023.107280_b0070","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2023.107280_b0075","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107280_b0080","unstructured":"Heudel P, Chabaud S, Perol D, et al. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer. ESMO Open. 2021 Feb;6(1):100044. 10.1016\/j.esmoop.2020.100044. Epub 2021 Jan 27. PMID: 33516148."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107280_b0085","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.annonc.2020.09.001","article-title":"Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer","volume":"31","author":"Heudel","year":"2020","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107280_b0090","doi-asserted-by":"crossref","first-page":"e2028627","DOI":"10.1001\/jamanetworkopen.2020.28627","article-title":"Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016","volume":"3","author":"Deng","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lungcan.2023.107280_b0095","doi-asserted-by":"crossref","unstructured":"Heudel P, Chabaud S, Perol D, Ray-Coquard I, Blay JY. Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor 'Checkpoint inhibition: protecting against or predisposing for second primary tumors?' by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs. Ann. Oncol. 2021 Aug;32(8):1055-1057. 10.1016\/j.annonc.2021.04.017. Epub 2021 Apr 28.","DOI":"10.1016\/j.annonc.2021.04.017"},{"issue":"2","key":"10.1016\/j.lungcan.2023.107280_b0100","doi-asserted-by":"crossref","first-page":"e023568","DOI":"10.1136\/bmjopen-2018-023568","article-title":"The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)","volume":"9","author":"P\u00e9rol","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107280_b0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav. Res."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107280_b0110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/cer-2020-0013","article-title":"Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants","volume":"9","author":"Allan","year":"2020","journal-title":"J. Comp. Eff. Res."},{"issue":"15","key":"10.1016\/j.lungcan.2023.107280_b0115","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/cncr.33558","article-title":"Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers","volume":"127","author":"Anderson","year":"2021","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.lungcan.2023.107280_b0120","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2020.23130","article-title":"Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States","volume":"324","author":"Sung","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107280_b0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/curroncol28010035","article-title":"The Impact of Radiotherapy on the Incidence of Secondary Malignancies: A Pan-Cancer Study in the US SEER Cancer Registries","volume":"28","author":"Li","year":"2021","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107280_b0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2023.107280_b0135","doi-asserted-by":"crossref","unstructured":"Sibylle Loibl, Andreas Schneeweiss, Jens Bodo Huober, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline\/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J. Clin. Oncol. 2021 39:15_suppl, 506-506. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.506.","DOI":"10.1200\/JCO.2021.39.15_suppl.506"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:36Z","timestamp":1759237476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":27,"alternative-id":["S0169500223008188"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107280","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced risk of secondary primary extra pulmonary cancer in advanced\/metastatic lung cancer patients treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107280"}}